Several experimental studies have demonstrated that the antioestrogenic action is only one of the great variety of mechanisms responsible for the antineoplastic properties of tamoxifen (TMX) in breast cancer. Oestrogens themselves would stimulate breast cancer growth by determining the paracrine release of growth factors, such as insulin-like growth factor 1 (IGF-1) (Furlanetto and Decarlo, 1984; Duclos et al., 1989) . Recent (Bonneterre et al., 1990) , and their presence seems to have a positive prognostic significance. Moreover, it has been demonstrated that TMX therapy reduces IGF-1 blood levels in breast cancer patients, and this event may contribute to the therapeutic effect of TMX itself (Pollak et al., 1990) . Another growth factor for breast cancer is prolactin (PRL). High levels of PRL have been proven to be associated with a poor prognosis in metastatic breast cancer patients (Bhatavdekar et al., 1990) , while the expression of PRL receptor on breast cancer cells constitutes a good prognostic factor (Bonneterre and Peyrat, 1989) . However, the role of PRL and PRL receptor in breast cancer is still controversial.
Recent advances in endocrinology have documented that the endocrine secretions are under a modulatory control exerted by the pineal gland (Regelson and Pierpaoli, 1987) , mainly through the circadian release of its most investigated hormone melatonin (MLT). MLT has been proven to stimulate oestrogen receptor (ER) expression on breast cancer cells (Danforth et al., 1983) and to reverse some malignant phenotypic characteristics of cancer cells (Hill and Blask, 1988) , perhaps by inhibiting oncogene expression, which would be responsible for the malignant characteristics themselves. Finally, MLT appears to inhibit the secretion of IGF-I and PRL (Regelson and Pierpaoli, 1987) , both involved in the stimulation of breast cancer cell proliferation. Other endocrine secretions are influenced by MLT, particularly growth hormone and cortisol (Regelson and Pierpaoli, 1987) . Therefore, several effects exerted by MLT, (Hill et al., 1992) . In addition, MLT has been proven to have a direct cytostatic action against some breast cancer cell lines (Hill and Blask, 1988 , 1989, 1991) . Moreover, MLT was given during the dark period of the day because of its greater biological efficacy in this period of the day (Regelson and Pierpaoli, 1987 Routine laboratory tests were repeated at weekly intervals for the first 3 months, then every month. Moreover, serum levels of IGF-1 and PRL were also measured before treatment and at 1 month intervals for the first 3 months. IGF-l and PRL serum levels were measured in duplicate by the radioimmunoassay (RIA) method and commercially available kits. Intra-assay and inter-assay coefficients of variation were less than 3% and 5% respectively. Normal values obtained in our laboratory (95% confidence limits) for IGF-1 and PRL were less than 2.2 U ml' and less than 20 ng ml-' respectively. Data were statistically analysed by the chi-square test, the Student's t-test and analysis of variance as appropriate.
Results
The characteristics of patients and their clinical response are reported in Table I . All patients were evaluable for response. No CR was achieved. PR was obtained in four patients (28.5%) (median duration: 8 months, range 3-9). The first two patients had single lung nodular metastasis; the third patient showed a cytologically positive pleural effusion and pleural infiltration documented by CT scan; the last patient had multiple skin metastases. No significant difference in tumour response rate was seen between patients with positive and negative ER (2/8 vs 2/6). Eight other patients had SD, whereas the remaining two patients had progression. All patients were followed-up for at least 1 year. Survival for longer than 1 year from the onset of treatment was observed in 10/14 patients.
No toxicity was found. On the contrary, most patients experienced a relief of anxiety; moreover, a relief of depressant symptoms occurred in 3 patients. Finally, two other Tamoxen plus melatonin in breast cancer P Lissoni et al 0 855 patients with low PS, as evaluated according to Karnofsky's score, had a clear improvement in their PS and quality of life on treatment. The improvement in the quality of life was based on specific patient report.
Changes in mean serum levels of IGF-1 observed on study are illustrated in Figure 1 . Mean concentrations of IGF-1 significantly decreased on treatment with respect to the values found before therapy. Moreover, minimum values (mean ± s.e.) of IGF-1 levels observed on therapy were significantly lower in patients who responded than in those with SD or progression (0.7 ± 0.3 vs 3.1 ± 0.6 U ml1, P < 0.05), whereas no significant difference was seen before therapy (3.9 ± 0.6 vs 4.7 ± 0.9). Mean PRL levels also significantly decreased on treatment with respect to the pretreatment ones (13 ± 2 vs 25 ± 3 ng ml-', P<0.05), even though no difference was observed in mean PRL decrease between responding patients and those with progression or SD (14±5 vs 11±4ngml-').
Discussion
This preliminary phase II study would suggest that the pineal hormone MLT may amplify the therapeutic efficacy of TMX in women with metastatic breast cancer and induce objective 4- However, measurements of other prognostic variables, such as progesterone and MLT receptors, will have to be evaluated to better define possible predictive factors for MLT efficacy. Therefore, because of its complete lack of toxicity, the combination of TMX and MLT could constitute a new effective modality of therapy for metastatic breast cancer, particularly in patients unable to tolerate conventional chemotherapies. Moreover, the results of this study, by showing declines in blood levels of tumour growth factors IGF-I and PRL, would suggest that MLT may amplify TMX activity by blocking the production of important growth factors for breast cancer. However, the IGF-1 decrease observed in this study may be due not only to MLT action, but also at least in part to TMX itself, since TMX has been proven to inhibit IGF-I secretion (Pollak et al., 1990) . In any case, the action of MLT on IGF-I secretion could explain the potential efficacy of the pineal hormone in patients with negative ER states. Recently, MLT receptors have been documented on some cancer cell lines (Hill et al., 1992) . Therefore, further studies, by investigating the expression of MLT receptors and by analysing their existence in relation to ER, PRL and IGF-1 receptors, will be required to predict the efficacy of this pineal hormone in breast cancer. Obviously, the small number of patients considered in this study does not allow us to draw definite conclusions about the possible use of MLT to modulate the efficacy of breast cancer endocrine therapy. However, the evidence of objective tumour regressions induced by concomitant MLT treatment in breast cancer patients who did not respond to a previous therapy with TMX alone would confirm the oncostatic properties of MLT. This study does not allow us to establish whether tumour regression is due to MLT alone or to its combination with TMX. Previous studies have shown that MLT may decrease oestrogen levels in breast cancer (Regelson and Pierpaoli, 1987) , but it is generally unable to induce objective tumour regression as a single agent (Lissoni et al., 1989 (Lissoni et al., , 1991 . In addition, the contribution of a TMX withdrawal effect cannot be excluded, even though it is generally unlikely in patients non-responsive to TMX alone. In conclusion, randomised studies with TMX alone vs MLT alone vs their combination will be required to better define the influence of the pineal hormone on TMX anti-tumour activity.
